Abstract
BackgroundThe GO-PRACTICE study was initiated to describe the use of Golimumab (GLM), a human anti-TNFα monoclonal antibody, in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
